Source: American journal of cardiovascular drugs. Unidade: FM
Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FATORES DE RISCO
ABNT
FERRARI, Filipe et al. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future. American journal of cardiovascular drugs, v. 22, n. 4, p. 363-383, 2022Tradução . . Disponível em: https://doi.org/10.1007/s40256-021-00515-4. Acesso em: 14 nov. 2024.APA
Ferrari, F., Scheffel, R. S., Martins, V. M., Santos Filho, R. D. dos, & Stein, R. (2022). Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future. American journal of cardiovascular drugs, 22( 4), 363-383. doi:10.1007/s40256-021-00515-4NLM
Ferrari F, Scheffel RS, Martins VM, Santos Filho RD dos, Stein R. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future [Internet]. American journal of cardiovascular drugs. 2022 ; 22( 4): 363-383.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1007/s40256-021-00515-4Vancouver
Ferrari F, Scheffel RS, Martins VM, Santos Filho RD dos, Stein R. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future [Internet]. American journal of cardiovascular drugs. 2022 ; 22( 4): 363-383.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1007/s40256-021-00515-4